dromlakhani Use questionnaires for hypogonadism screening with caution
STEP 1 — Gather Information
Collect patient's presenting symptoms (e.g., low libido, erectile dysfunction, decreased morning erections, fatigue, decreased energy, mood changes) and risk factors (obesity, metabolic syndrome, HIV, opioid/glucocorticoid use). Note that questionnaires are not recommended for universal screening.
STEP 2 — Rule In / Rule Out
If the patient is asymptomatic for hypogonadism, do not administer a screening questionnaire; proceed to routine care. If symptomatic, consider administering a questionnaire only to raise suspicion, but plan to confirm with laboratory testing.
STEP 3 — Classify or Stratify
Use questionnaire score to stratify suspicion (high vs low) but recognize low specificity; high score increases pre-test probability, low score does not rule out disease. Combine with clinical risk factors to decide on testosterone testing.
STEP 4 — Decide
Obtain a morning total testosterone level (fasting, 07:00–11:00) using a reliable assay; if <12 nmol/L, repeat on a separate day; if persistently low, diagnose hypogonadism and consider testosterone therapy after shared decision‑making.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on questionnaire results alone to diagnose or exclude hypogonadism; low specificity yields many false positives; avoid universal screening in the general male population; reserve questionnaire use for high‑risk groups (e.g., metabolic disease, HIV, opioid use) and always confirm with serum testosterone.
Concrete Clinical Example
A 58‑year‑old man with type 2 diabetes and fatigue completes the ADAM questionnaire (score ≥ 3, suggesting possible hypogonadism). The clinician orders a morning total testosterone, which returns 10.5 nmol/L. A repeat measurement a week later is 10.8 nmol/L. Hypogonadism is diagnosed, and testosterone therapy is discussed.
Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, https://doi.org/10.1093/sxmrev/qeaf036